PDS Biotech was established after the opportune and unexpected discovery that positively charged cationic lipids, being studied in the unrelated field of gene therapy, elicited a powerful immune response. The PDS Biotech scientific team observed that these cationic lipids efficiently induced the body to produce targeted killer T-cells. This was a major accomplishment that had previously been a significant hurdle impeding the effectiveness of immunotherapy technologies to effectively harness the body’s immune system to fight cancer. PDS Biotech’s team then studied all the underlying biologic mechanisms related to how specific cationic lipids interacted in the body and used that proprietary knowledge to engineer Versamune® to optimize its cancer-fighting effectiveness.
PDS Biotech is developing multiple therapies based on the Versamune® platform, which has been designed to help the body better recognize, attack and destroy cancer. PDS Biotech’s pipeline combines the Versamune® technology with custom-designed tumor-specific antigens, each tailored to specific cancer types. An antigen is a protein specific to cancer cells or highly expressed by cancer cells, which can be recognized by the immune system. When combined with Versamune®, the body’s immune system produces antigen-specific T-cells in response to the treatment to fight and kill the cancer.
PDS Biotech has partnered with some of the leading institutions in cancer research to advance clinical testing of PDS Biotech products in multiple cancers.